Fulcrum Therapeutics to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, July 31, 2024, at 8:00 a.m. ET
Fulcrum Therapeutics (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases, has announced its plans to release second quarter 2024 financial results on Wednesday, July 31, 2024, before U.S. financial markets open. The company will host a conference call and webcast at 8:00 a.m. ET on the same day to discuss the results and provide updates on recent corporate developments.
Interested parties can register for the conference call through a provided link, which will give them dial-in details and a unique PIN for access. An audio webcast will also be available through the company's Investor Relations section on their website.
Fulcrum Therapeutics (Nasdaq: FULC), una azienda biofarmaceutica in fase clinica focalizzata nello sviluppo di piccole molecole per malattie rare geneticamente definite, ha annunciato i suoi piani di pubblicare i risultati finanziari del secondo trimestre 2024 il mercoledì 31 luglio 2024, prima dell'apertura dei mercati finanziari negli Stati Uniti. L'azienda ospiterà una chiamata in conferenza e una webcast alle 8:00 a.m. ET lo stesso giorno per discutere i risultati e fornire aggiornamenti sugli sviluppi aziendali recenti.
Le parti interessate possono registrarsi per la chiamata in conferenza tramite un link fornito, che darà loro i dettagli per la chiamata e un PIN unico per l'accesso. Un audio webcast sarà anche disponibile nella sezione Relazioni con gli Investitori del sito web dell'azienda.
Fulcrum Therapeutics (Nasdaq: FULC), una empresa biofarmacéutica en fase clínica centrada en el desarrollo de pequeñas moléculas para enfermedades raras definidas genéticamente, ha anunciado sus planes para publicar los resultados financieros del segundo trimestre de 2024 el miércoles 31 de julio de 2024, antes de que abran los mercados financieros en EE. UU. La empresa organizará una llamada de conferencias y un webcast a las 8:00 a.m. ET el mismo día para discutir los resultados y proporcionar actualizaciones sobre los desarrollos corporativos recientes.
Las partes interesadas pueden registrarse para la llamada de conferencias a través de un enlace proporcionado, que les dará los detalles de marcación y un PIN único para el acceso. También estará disponible un audio webcast a través de la sección de Relaciones con Inversores en el sitio web de la empresa.
Fulcrum Therapeutics (Nasdaq: FULC)는 유전적으로 정의된 희귀 질환을 위한 소분자를 개발하는 데 중점을 둔 임상 단계의 생물 의약품 회사로, 2024년 2분기 재무 결과를 2024년 7월 31일 수요일에 미국 금융 시장 개장 전에 발표할 계획이라고 발표했습니다. 회사는 같은 날 동부 표준시 오전 8:00에 재무 결과와 최근 기업 개발에 대한 업데이트를 논의하기 위한 컨퍼런스 콜 및 웹캐스트를 주최할 것입니다.
관심 있는 당사자는 제공된 링크를 통해 컨퍼런스 콜에 등록할 수 있으며, 이 링크를 통해 전화 연결 세부정보와 액세스를 위한 고유 PIN을 받을 수 있습니다. 또한 회사 웹사이트의 투자자 관계 섹션을 통해 오디오 웹캐스트도 제공될 예정입니다.
Fulcrum Therapeutics (Nasdaq: FULC), une entreprise biopharmaceutique en phase clinique axée sur le développement de petites molécules pour les maladies rares définies génétiquement, a annoncé ses projets de publier les résultats financiers du deuxième trimestre 2024 le mercredi 31 juillet 2024, avant l'ouverture des marchés financiers américains. L'entreprise organisera une conférence téléphonique et un webcast à 8h00 ET le même jour pour discuter des résultats et fournir des mises à jour sur les récents développements de l'entreprise.
Les parties intéressées peuvent s'inscrire à la conférence téléphonique via un lien fourni, qui leur donnera les détails de connexion et un code PIN unique pour l'accès. Un audio webcast sera également disponible dans la section Relations avec les Investisseurs sur le site Web de l'entreprise.
Fulcrum Therapeutics (Nasdaq: FULC), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von kleinen Molekülen für genetisch definierte seltene Krankheiten konzentriert, hat angekündigt, am 31. Juli 2024 vor Eröffnung der US-Finanzmärkte die Finanzergebnisse des zweiten Quartals 2024 zu veröffentlichen. Am selben Tag wird das Unternehmen um 8:00 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um die Ergebnisse zu besprechen und über aktuelle Unternehmensentwicklungen zu informieren.
Interessierte Parteien können sich über einen bereitgestellten Link für die Telefonkonferenz registrieren, der ihnen die Einwahldaten und eine einzigartige PIN für den Zugang geben wird. Ein Audio-Webcast wird auch im Bereich Investor Relations auf der Website des Unternehmens verfügbar sein.
- None.
- None.
CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its second quarter 2024 financial results will be released on Wednesday, July 31, 2024, before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.
Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and unique PIN which will allow them to access the call. An audio webcast will be accessible through the Investor Relations section of the company’s website at www.fulcrumtx.com or by clicking here. Following the live webcast, an archived replay will also be available.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule in development for the treatment of facioscapulohumeral muscular dystrophy (FSHD), and pociredir, a small molecule designed to increase expression of fetal hemoglobin and in development for the treatment of sickle cell disease (SCD) and other hemoglobinopathies. Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.
Contact:
Chris Calabrese
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com
917-680-5608
FAQ
When will Fulcrum Therapeutics (FULC) release its Q2 2024 financial results?
What time is Fulcrum Therapeutics' (FULC) Q2 2024 earnings call scheduled for?
How can investors access Fulcrum Therapeutics' (FULC) Q2 2024 earnings call?
What is Fulcrum Therapeutics' (FULC) primary focus as a company?
